8-K current report · filed Jul 30, 2026

Neurocrine Biosciences Inc (NBIX) 8-K Current Report: July 30, 2026

Item 2.02Item EX-99.1NBIX overview

Short answer

Neurocrine Biosciences Inc (NBIX) filed an 8-K current report with the SEC on July 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026 announced.

Neurocrine Biosciences Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced
  • Full earnings details and management commentary in Exhibit 99.1
  • Results announcement provides the basis for updating revenue, profitability and outlook expectations

Item EX-99.1 · Exhibit EX-99.1

  • Q2 revenue $959M, up 39% YoY, led by INGREZZA $716M, CRENESSITY $184M and newly acquired VYKAT XR $54M
  • INGREZZA 2026 sales guidance raised to $2.825B-$2.875B from $2.7B-$2.8B, signaling stronger demand and commercial momentum
  • Soleno acquisition completed for $2.9B, adding VYKAT XR and expanding rare-disease exposure, but reducing cash and securities to $482M
  • GAAP EPS $1.39 versus $1.06, while non-GAAP EPS reached $2.85 versus $1.65, aided by acquisition-related exclusions
  • 2026 GAAP R&D guidance increased to $1.275B-$1.325B and SG&A to $1.575B-$1.6B, reflecting pipeline investment and VYKAT XR commercialization costs

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Neurocrine Biosciences Inc 8-K filings

Get the next NBIX 8-K as it lands

Follow NBIX for push alerts, or ask the research agent what this filing means.